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Abstract
Background: The  human immunodef ic iency 
virus/acquired immunodeficiency syndrome pandemic 
have posed a significant public health challenge to the 
global community. Massive therapeutic interventions with 
antiretroviral drugs are being undertaken, yet problems 
and challenges exist. This review examines these 
problems and challenges as they affect the treatment of 
HIV infection in resource-poor countries such as Nigeria.
Methods:   The information was sourced from relevant 
literature using human immunodeficiency virus/acquired 
immunodeficiency syndrome journals, textbooks and 
Websites on human immunodeficiency virus/acquired 
immunodeficiency syndrome, highly active antiretroviral 
therapy, resource-poor countries as key words. 
Results: Several studies have shown that the advent of 
highly active antiretroviral therapy in 1996 has 
significantly reduced morbidity and mortality among 
people living with HIV/AIDS (PLWHA). But in resource-
poor countries, initiation and maintenance of highly active 
antiretroviral therapy has been associated with many 
challenges and problems such as: poor infrastructural 
base for the control programs; irregular or non availability 
of drugs; poor drug adherence; co-morbidities and 
opportunistic infections/malignancies; drug toxicities; 
drug/food and drug/drug interactions; laboratory 
monitoring of viral load; CD4 cell counts; full blood counts; 
electrolytes, kidney and liver functions. 
Conclusion: The review has shown that the solution to 
the pandemic lies in a multi-sectoral and holistic approach 
involving International and local agencies, and 
communities.
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Introduction 
Globally the HIV prevalence has reached pandemic 
proportions with sub-Saharan Africa accounting for about 
25 million of the total 40 million people living with 
1HIV/AIDS (PLWHA) as at 2006 . More than 60% of these 
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infected people are in the age group 15-49 years. In 
Nigeria the adult prevalence had increased from 1.8% 
in 1991 to 4.5% in 1995, and 5.8% in 2001 before 
2
dropping to 5.4% in 2003 and 4.4% in 2005 .The fight 
against HIV/AIDS poses enormous challenges 
worldwide, generating fears that success in its control 
3
may be too difficult or even impossible to attain . 
However, the advent of highly active antiretroviral 
therapy (HAART) in 1996 has significantly reduced 
morbidity and mortality, prolonged life expectancy, and 
4
improved quality of life among PLWHA . HAART has 
also been effective in the prevention of mother-to-child 
 5transmission of HIV (PMTCT) .
The Goals of Antiretroviral Therapy
The goals of antiretroviral therapy (ART) are to provide 
optimal and individualized treatment for HIV-infected 
people at all stages of the disease, and in the process 
reduce the infectiousness of these individuals. These 
6 
goals are conceptualized in five ways thus ; the 
prevention of disease progression, prolongation of life 
and improvement in quality of life (clinical goals); the 
greatest possible reduction of the viral load to below 
detectable limits, preferably to < 50 copies per ml of 
blood (virologic goals ); restoration of the immune 
system both in quantity (normal CD4+ cell counts) and 
in quality ( normal cell mediated functions) 
(immunologic goals) ; rational sequencing of drugs in a 
fashion that will achieve clinical, virologic, and 
immunologic goals while maintaining treatment 
options, minimizing drug toxicities and maximizing 
adherence to therapy (therapeutic goals);and lastly 
reduction of HIV transmission ( epidemiologic goals).
7
In pursuance of these goals, HAART  which involves 
the combination of three or more drugs from at least two 
different groups or classes are used so that the drugs 
can act on at least two different points in the life cycle of 
the virus. The introduction of these drugs, and their 
widespread use in the developed countries of Europe 
and America, has changed the gloomy picture of 
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HIV/AIDS in these developed economics where the 
incidence of AIDS decreased from 30.7 to 2.5 per 100 
patient years with attendant improvements in the quality of 
8
life of the patients . But this is not the picture or situation in 
Africa. In this continent, especially sub-Saharan Africa, 
the disease is still on rampage, maiming and killing 
majority of the workforce and leaving many children as 
9orphans . This situation is consequent upon many factors 
some of which are discussed below.
Some Benefits of HAART. 
HAART has become the standard of care for treatment of 
HIV infection and has significantly reduced morbidity and 
 mortality among PLWHA as well as prevention of mother-
10. to-child transmission of HIV It has also created a major 
incentive for people to participate in voluntary counseling 
and testing with the knowledge and belief that 
uninterrupted HAART prevents progression of HIV 
11
infection to AIDS and therefore reducing stigmatization . 
Fear, ignorance and confusion about the infection and its 
treatment are being replaced by optimism and positive 
living when PLWHA, their spouses, families, support 
groups and communities observed the reduced morbidity 
and mortality and improved quality of life associated with 
12HAART . The massive scaling up of the Nigerian national 
ARV programs with support from the 3 by 5 Initiative of the 
 13World Health Organisation (WHO) ; the Global Fund to 
14 15
Fight AIDS, Tuberculosis, and Malaria ; the World Bank ; 
and the United States President's Emergency Plan for 
 16AIDS Relief (PEPFAR)  has ensured the availability of 
ARVs as well as the provision of ancillary laboratory 
services both for diagnostic and monitoring purposes at 
little or no cost to the patients. 
Clinical Eligibility Criteria for Initiation of 
HAART in Resource  Limited Settings
Until 2005, only 5% of the over six million people who 
required ART in resource limited countries could have 
 17
access to the antiretroviral (ARVs) . Between 2003 and 
2005, these numbers increased three-fold, mainly from 
the massive scaling up of programs supported by the 3 by 
5 Initiative of the World Health Organisation (WHO); the 
Global Fund to Fight AIDS, Tuberculosis, and Malaria; the 
World Bank; and the United States President's 
Emergency Plan for AIDS Relief (PEPFAR). In Nigeria 
with a seroprevalence of 4.4% in 2005 and about 800,000 
people in urgent need of ART, fewer than 250,000 adults 
18and children were yet to access these drugs by 2006 . 
In developing countries, clinical eligibility criteria for ART 
have varied based on several factors.  These factors 
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include patients' educational and socio-cultural 
background, lifestyle and readiness to take ART 
regularly for life, WHO clinical staging, baseline CD4+ 
cell count, total lymphocyte count (in the absence of 
CD4+ cell count)  and hemoglobin concentrations, co-
morbidities (viral hepatitis, tuberculosis etc.), 
19
childbearing potential and HIV RNA levels (viral load) .  
  The WHO 2002 guidelines for initiation of HAART in 
resource -poor countries have been modified to 
20
include :
· Patients with CD4+T lymphocyte counts equal to 
3 
or less than 200 cells/mm irrespective of WHO 
clinical staging;
· Patients with WHO stage 4 disease (AIDS defining 
illness), irrespective of CD4+T lymphocyte count 
or total lymphocyte count; 
· Patients with WHO clinical stage 3 disease 
(symptomatic HIV) with CD4+ T lymphocyte 
3 
counts of less than 350 cells/mm
· Patients with WHO clinical stage 1 or 2 disease 
with CD4+ lymphocyte counts of less than 200 
3
cells/mm
· Patients with WHO clinical stage 2 or 3 disease 
3 
with total lymphocyte counts of = 1,200/mm and 
hemoglobin of = 10 g/dl (when CD4 count is 
unavailable).
· In these countries, assessment of HIV viral load is 
not considered essential for determining the need 
for therapy. However, especially in developed 
economics, ART can be initiated at viral load 
above 30,000 copies/ml or > 55,000 copies/ ml by 
branched DNA or RT-PCR respectively, 
21irrespective of CD4+ lymphocyte counts .
Choice of Antiretroviral Regimens in 
Resource -Limited Settings
In January 2002, the Nigerian Government launched a 
National ARV program under the WHO 2002 guidelines 
for initiation of HAART in resource poor countries. The 
guidelines recommended  a protease inhibitor-sparing  
ART consisting  of  two nucleoside reverse 
transcriptase inhibitors (NRTIs) plus one non- 
nucleoside reverse transcriptase inhibitors (NNRTI) as 
first line regimen. In Nigeria today, most of the 
government and non-governmental assisted ARV drug 
programs are based on the preferred first-line regimen-: 
Two NRTIs (zidovudine or stavudine + lamivudine) + 
 22one NNRTI (nevirapine or efavirenz) . The availability 
of cheaper generic ARV drugs, in contrast to the costly 
branded ones, have enabled many developing 
363
countries to initiate national ARV program and to add 
alternative first- line regimens, based on:
(i) Two NRTIs e.g., abacavir (ABC) + lamivudine (3TC) 
or emtricitabine (FTC); plus one NNRTI e.g., 
 23nevirapine (NVP) or efavirenz (EFV)  or 
(ii) One nucleotide reverse transcriptase inhibitor 
(NtRTI) e.g., tenofovir disoproxil fumarate (TDF); 
plus one NRTI (3TC or FTC), plus one NNRTI (NVP 
 24, 25or EFV) . 
These ARVs are a new set of drugs with various degrees 
of potencies and toxic or side effects and their extensive 
use are expected to present new clinical problems for the 
26, 27
patients and health care providers . Therefore, these 
regimens were chosen as first-line for developing 
countries because of their potency and durability. Other 
considerations were: their low pill burden; minimal food 
requirements and refrigeration storage needs; co-
formulations with high mutational thresholds; once or 
twice daily oral dosing; good tolerability; high resistance 
profile; good pharmacokinetic profile; minimal toxicity and 
28cost .
29
Based on a review of data from a number of studies , the 
globally preferred initial HAART combinations for adults 
are:  EFV in combination with 3TC and either ZDV or d4T, 
or TDF; or Ritonavir boosted Lopinavir (LPV/r) in 
combination with 3TC and either ZDV or d4T. Recently, 
however, clinicians have been advised to avoid d4T as a 
first-line therapy or alternatively give the lower dose of 
30mg irrespective of patients' weight, because of its long-
30
term cumulative toxic effects . 
Challenges of ART maintenance in Resource- 
Limited Settings
HIV specialists have estimated that 10 to 60 years of 
sustained and uninterrupted ART using current protocols 
31
might lead to eradication of the virus in an individual , but 
many workers think that this may be a mirage, because 
even in developed economies where there are now many 
effective HAART regimens for the treatment of HIV 
infection, there are many problems associated with the 
32ARVs and the current ART protocols . First, current ARVs 
do not cure HIV infection and therefore the drugs must be 
33
taken for life .  Second, the current ART has many risks 
and limitations. The complexity of the treatment regimen 
34makes it difficult for the uneducated to comprehend .  In 
sub-Saharan Africa and other developing countries, 
socio-cultural beliefs and practices some of which 
inadvertently encourage the transmission and spread of 
35 36
HIV , low literacy level , unawareness, outright rejection 
37 38/or poor understanding of the pandemic , poverty , 
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diseases, none or poor adherence to antiretroviral 
39therapy , all of these contribute to poor treatment 
outcomes or failures. The cost of the drugs, non-
availability or irregular supply of potent antiretroviral 
drugs and poor storage facilities pose major financial 
40challenges . The lack of an adequate health 
infrastructure, insufficient human resources and official 
apathy create serious obstacles to laboratory 
monitoring of diseases and providing ART in an 
41, 42
effective, durable, and sustainable manner .
Early and delayed adverse effects such as 
gastrointestinal disturbances, metabolic disorders, 
mitochondrial toxicities, peripheral neuropathies, and 
numerous organ-specific adverse reactions are 
continued concerns. The scope of these adverse 
effects is quite wide and broad and our understanding of 
their pathogenesis and clinical presentations continue 
43to evolve . Unfavorable interactions have been shown 
to occur among the antiretroviral drugs and between 
them and other drugs given for treatment of 
opportunistic infections, complications of the disease 
44and other co-morbidities . Drug resistances of various 
forms (mono-, dual-, triple, multi-and cross-) occur for 
various reasons, foremost being poor adherence to 
45, 46therapy .
For these reasons, it is widely accepted that current 
treatment approach is incapable of eradicating HIV 
completely from the blood, even when the plasma viral 
load is undetectable with current technological means. 
This is said to be partly due to the persistence of latently 
infected resting or memory CD4+ cell populations in 
lymph nodes, skin and glia tissues which rapidly 
repopulates the plasma at the slightest opportunity with 
47consequent  rebound viremia . It is also thought that 
prolonged suppression of the viral load by antiretroviral 
therapy impairs the development of HIV specific 
immune responses because of persistent sub-optimal 
antigenic stimulation leading to rapid rebound of plasma 
48
viremia when treatment is interrupted . This 
phenomenon has been confirmed by a study which 
demonstrated viral replication in the semen of 23% of 
49
patients on HAART . 
Other Challenges and Problems  
Drug toxicities
Toxicities or side effects caused by ART can be 
50
classified into three broad categories .
First category are mild and transient symptoms such as 
headaches, gastric upset ,nausea, fatigue, mild 
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rash(without constitutional symptoms) and the central 
nervous system (CNS) disturbances seen with EFV. 
These often require patient assurance that symptoms are 
common and will decrease over time. ART interruption is 
seldom indicated in this condition. Second category 
symptoms are more severe and often respond to some 
medical intervention. ART interruption is usually not 
indicated and often symptomatic treatment will suffice. 
These symptoms include more severe headaches, 
severe gastric upset with nausea and vomiting, and 
peripheral neuropathy, not incapacitating or interfering 
with daily activities of living. In the third category, 
symptoms are so severe that ART must be stopped and 
replaced by alternative drugs. These symptoms include 
anemia (hemoglobin <7.5 gm/dl or a rapidly falling 
hemoglobin that drops by 2 gm/dl from baseline) as can 
occur with the use of  ZDV; nausea with severe discomfort 
and minimal intake of drugs for 3 or  more days, vomiting 
severe enough to lead to dehydration or inability to ingest 
food and drugs for 24 hours, severe headache not 
responsive to non-narcotic analgesics, fatigue reducing 
activity by more than 50%, hypersensitivity reactions and 
grade 3 hepatotoxicity or a 5- fold increase in level of 
transaminases above the upper limit.  ABC and NVP 
hypersensitivity reactions belong to this category. 
ABC hypersensitivity which occurs in 3-8% of patients can 
51
be fatal if patient is re-challenged with the drug . The 
symptoms include shortness of breath, cough, fever, 
a c h e s ,  f a t i g u e ,  l e t h a r g y,  b o d y  s w e l l i n g ,  
abdominal/stomach pain, diarrhea, nausea, malaise, 
52
muscle or joint aches, numbness, sore throat and rash . 
Severe NVP hypersensitivity reactions occurs in the form 
of Stevens-Johnson Syndrome with  severe erythema 
multiforme,urticaria,desquamation of skin, skin blistering 
and sloughing, exfoliative dermatitis ,anaphylaxis, 
mucous membranes involvement, angioedema ,and  
cracked/fissured lips. Systemic signs include body aches, 
arthralgia, myalgias, fevers, lymphadenopathy and 
significantly elevated hepatic transaminases, or frank 
fulminant hepatitis. These reactions can occur in up to 
20% of patients and usually in the first 6-8 weeks of 
therapy, especially if initiated in women and men with CD4 
3 3 27, 53count >250 cell/mm and >400 cells/mm respectively . 
Therefore, NVP should be avoided in these patients, and 
in the absence of facilities for CD4 cell count, should be 
initiated at a lower dose of 200mg per day for the first 2 
weeks, so that if there is no hypersensitivity reaction, the 
dose is increased to 200mg twice daily. Once this 
condition occurs, all ART are stopped and patient is 
treated with intravenous fluids, high dose prednisolone 
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and antihistamines. On recovery, ARV drugs are re-
introduced but without NVP which must never be re-
introduced.
Anti-retroviral Toxic Neuropathy (ATN) also called ARV-
associated distal symmetrical polyneuropathy (DSP) is 
54caused by the dideoxynucleoside NRTIs such as d4T , 
 55  56     didanosine (ddl) , zalcitabine (ddc) and occasionally 
26   
3TC . The frequency is 5-24% and is dose related, 
occurring more in patients with advanced HIV infection 
+ 3
(CD4  count less than 200 cells/mn ), or who have 
previously experienced peripheral neuropathy either 
clinically or sub-clinically before initiation of anti-
retroviral therapy . The clinical features are 
  
indistinguishable from those of HIV-associated DSP,  
but the onset of symptoms may provide useful 
information about the aetiology. This is because AIDS-
related DSP may take months to years to develop while 
ATN tends to evolve more rapidly within a week to six 
months of therapy and usually resolves if the drug is 
withdrawn, although recovery may be generally slow. 
Occasionally, symptom intensification lasting four to 
eight weeks may occur before eventual improvement. 
Combination therapy with stavudine and didanosine or 
zalcitabine when given at lower dosages to patients with 
3
baseline CD4+ > 400 cells/mm  or with no prior history of 
57.  ARV therapy appears not to increase the risk of ATN
Management of ATN requires dose reduction or 
substitution to a less neurotoxic drug without sacrificing 
virologic control. In cases in which alternative non-
neurotoxic ARV agents are not available due to 
resistance or toxicity, and substitution is not possible 
without jeopardizing virologic control, symptomatic 
analgesic treatment while continuing ARV may be 
appropriate.
Drug-drug Interactions
The pharmacotherapy of HIV infection remains a 
challenging, long-term undertaking. The use of drugs 
that may have specific food and pH requirement, for 
optimal absorption, and that may be substrates, 
inhibitors and inducers of drug metabolism, yields an 
environment that is among the most complex in 
58contemporary therapeutics . Available ARV options for 
HIV-infected person who is receiving tuberculosis 
therapy with a Rifampicin- based regimen are 
59problematic and limited . Concomitant use of rifampicin 
with the protease inhibitors (PIs) is contra-indicated 
because significant reductions in PI concentrations 
occur as a result of rifampicin CYP450 enzyme 
60induction in the liver . To date, attempts to overcome 
rifampicin enzyme induction with increased doses of PIs 
365
and/ or ritonavir have not been successful in the case of 
atazanavir/ritonavir (ATV/R) or have been associated 
with high rates of hepatotoxicity, as seen with 
61, 62
Saquinavir/ritonavir (SQV/r) and LPV/r . Therefore 
either an NRTI-only regimen or an EFV- based regimen is 
59
considered the best ARV option in this setting . Another 
option is the use of rifabutin with NNRTIs and PIs in 
patients co-infected with HIV and tuberculosis. Rifabutin 
is metabolized by hepatic CYP3A enzyme which is 
induced by EFV but inhibited by delavirdine (DLV) and 
PIs. As a result, rifabutin's dose has to be reduced if it is 
used with delavirdine or PIs and increased if it is used with 
EFV.  Rifabutin is not commonly used because of this 
63
pharmacokinetic complexities .
The PIs have some other limitations associated with their 
use. To be more effective, most PIs will need to be 
combined with ritonavir (also a PI) for pharmacokinetic 
64enhancement . This increases the pill burden, cost and   
side effects. Some of these drugs also require 
refrigeration storage. These requirements are 
impediments to effective ART in developing countries with 




The WHO defined antiretroviral treatment failure in terms 
of virologic failure, immunologic failure and clinical failure. 
Virologic failure is defined as failure of viral load (VL) to 
decrease by 1.5 to 0.7 log  c/mL within 4 weeks, or to 10
reduce <10000 c/mL after 16 to 24 weeks or < 50 c/mL by 
66
4 months of continuous ART  .  Immunologic failure (or 
CD4 cell count failure) is a confirmed 50% fall of CD4+ cell 
count or a 5 %  fall in CD4+ percentage, from on-therapy 
absolute CD4+ cell peak level or fall to baseline CD4+ cell 
3count ,or failure of  CD4+ cell count to rise above 100/mm  
without an identifiable medical cause to explain the low 
CD4 cell level . It has also been arbitrarily defined as 
3failure of the CD4 count to increase 25-50/mm  in the first 
67year of HAART .  Clinical failure is defined as occurrence 
or re-occurrence of an AIDS-defining opportunistic 
infection or malignancy in the presence of more than 6 
68months of regular antiretroviral therapy . VL, CD4 cell 
level and clinical stage of HIV are interrelated in many 
ways. Late stage (stage IV) HIV disease characterized by 
3VL > 10,000 c/mL and CD4 count < 200 cells/mm  is 
associated with the development of opportunistic 
infections, tumours, wasting and neurologic 
complications. Long-term studies show that virologic 
failure will eventually lead to immunologic and clinical 
failures, because sustained levels of viremia > 10,000 
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copies/mL is associated with clinical progression and 
69, 70rapid CD4+ cell decline .  
Many factors are responsible for ARV treatment failures 
in resource poor countries. First many patients present 
late at the AIDS stage of the disease with multiple co-
morbidit ies (tuberculosis, anemia, malaria, 
malnutrition, hepatitis etc.) requiring ingestion of many 
drugs. The attendant high pill burden and possible 
costs, frequent dosing schedule, drug interactions and 
toxicities   may cause treatment interruptions and affect 
39
adherence . Second, many patients travel long 
distances to be able to access HIV care and support, 
including ART. Financial constraints, unavailability of 
good and quick means of transportation, inconvenient 
c l in ic  appo in tments  and  long  queues  a t  
consulting/pharmacy rooms contribute to irregular clinic 
71, 72
attendance and consequent drug pick-up failures . 
Third, initiation of ART, without adequate counseling 
and education about the disease and its treatment, 
including opportunistic infection prophylaxis and 
treatment, is associated with poor adherence and 
treatment failure. Failure to correct false cultural beliefs 
about the disease or to reduce its associated 
stigmatization, poor family and social support systems, 
emotional instability and high risk lifestyles are 
73, 74additional factors .  
THE WAY FORWARD
Although many developing countries have adopted 
various programs to tackle the HIV/AIDS crisis, these 
programs are yet to achieve stated objectives because 
they are tailored toward the approaches dictated by the 
WHO and UNAIDS and not to the peculiarities of each 
75
country . Lack of strong political will and response to 
the HIV pandemic plagues these countries, many of 
which lack policies that ensure women's equal access 
to critical prevention and care services or legal 
measures to prohibit discrimination against PLWHA. 
Less than 50% of these countries have adopted 
comprehensive workplace policies addressing 
HIV/AIDS.  Only 40% have a national AIDS monitoring 
and evaluation plan, yet less than 25% have a national 
76AIDS monitoring and evaluation budget .
The solution to the pandemic lies in a multi-sectoral/ 
holistic approach with interconnectivity and 
partnerships between the International Agencies [the 
World Bank, WHO, Joint United Nations Program on 
HIV/AIDS (UNAIDS), United Nations Population Fund 
(UNFPA), etc], National Agencies [National Action 
Committee on AIDS (NACA), National AIDS and STD 
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Control Program (NASCP), etc], Civil Society 
Organizations [Society for Women and AIDS in Africa, 
Nigeria (SWAAN), Network of people with HIV/AIDS 
(NEPWHAN),etc], local communities, the private sector 
and individual support groups. These partnerships are 
expected to lead to a marked increase in international 
resources available for the AIDS response as well as the 
strengthening and broadening of national and local 
response to the HIV/AIDS program with attendant 
progress in strategies, policies, legislation, action, faith-
based leadership, and civil society and community 
mobilization.
The components of the health sector response should 
compose of the following:
(i) Informed policy and strategic development. This 
involves establishing or/and strengthening 
epidemiologic and behavioral surveillance for HIV 
and other sexually transmitted infections (STIs); 
elaborating plans to generate resources; 
strengthening accountability and monitoring 
systems for both human and financial resources; 
countering the stigmatization and discrimination of 
PLWHAs; reviewing policies, laws, and regulations 
pertaining to the HIV/AIDS programs such as legal 
reform advocacy and legal aid for PLWHAs; 
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mobilizing communities, non-governmental 
organizations, PLWHAs, vulnerable groups, and 
the business sector through mass media 
engagement.
(ii) Health standards and health systems. This should 
involve setting and promoting national standards 
for the public, private, and community-based 
delivery of HIV/AIDS prevention, health promotion, 
and treatment, support and care; building capacity 
and strengthening health systems; promoting 
universal safety precautions; and ensuring the 
safety of blood and blood products.
(iii) Prevention and health promotion. This entails 
providing support for the development of broad-
based programs to educate the general population 
about HIV/AIDS; promoting harm reduction, and 
safer and responsible sexual behavioral and 
practice (e.g., condom use promotion); and 
targeting interventions to high-risk groups, 
including counseling and testing.
(iv) Treatment. This incorporates expansion of access 
to antiretroviral drugs; prevention of mother-to-
child transmission of HIV; increasing access to 
services to diagnose and manage STIs and TB; 
and providing a continuum of care from home to 
health facility.
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